All In Biotech

Drug Trial Radar · NCT00657904

Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer

A Randomized Double-Blind Comparative Trial of Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer.

Last checked: Nov 19, 2026Latest source record: Jun 6, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 3,618 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,618

Actual

Start

Aug 1995

Primary completion

Jul 2008

Study completion Aug 2008

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Apr 14, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this trial is to study the effect - in terms of time to progression and overall survival - of 2 years of adjuvant bicalutamide 150mg monotherapy, versus placebo, in subjects with histologically or cytologically confirmed non-metastatic adenocarcinoma of the prostate gland.

Conditions

  • Non-metastatic Prostate Cancer

Interventions

  • BicalutamideDrug

    150mg daily

  • PlaceboDrug

    once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to clinical progressionTime frame: Throughout study period
  2. Overall patient survivalTime frame: Throughout study period

Locations

85 sites in 2 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Mobile, Alabama

  • Research Site

    Scottsdale, Arizona

  • Research Site

    Tucson, Arizona

  • Research Site

    Berkeley, California

  • Research Site

    Laguna Woods, California

  • Research Site

    Newport Beach, California

  • Research Site

    San Diego, California

  • Research Site

    San Francisco, California

  • Research Site

    Santa Monica, California

  • Research Site

    Thousand Oaks, California

  • Research Site

    Torrance, California

  • Research Site

    Van Nuys, California

  • Research Site

    Denver, Colorado

  • Research Site

    Middlebury, Connecticut

  • Research Site

    New Haven, Connecticut

  • Research Site

    Washington D.C., District of Columbia

  • Research Site

    Aventura, Florida

  • Research Site

    Bay Pines, Florida

  • Research Site

    Boca Raton, Florida

  • Research Site

    Daytona Beach, Florida

  • Research Site

    Fort Myers, Florida

  • Research Site

    Gainesville, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Ocala, Florida

  • Research Site

    Saint Augustine, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    Chicago, Illinois

  • Research Site

    Fort Wayne, Indiana

  • Research Site

    Greenwood, Indiana

  • Research Site

    Iowa City, Iowa

  • Research Site

    Kansas City, Kansas

  • Research Site

    Louisville, Kentucky

  • Research Site

    Shreveport, Louisiana

  • Research Site

    Greenbelt, Maryland

  • Research Site

    Rockville, Maryland

  • Research Site

    Burlington, Massachusetts

  • Research Site

    Newtown, Massachusetts

  • Research Site

    Ann Arbor, Michigan

  • Research Site

    Detroit, Michigan

Showing 40 of 85 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.